Protalix BioTherapeutics IncFind Ratings Reports
PROTALIX BIOTHERAPEUTICS INC's gross profit margin for the third quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. PROTALIX BIOTHERAPEUTICS INC is extremely liquid. Currently, the Quick Ratio is 5.17 which clearly shows the ability to cover any short-term cash needs. The company managed to increase its liquidity from the same period a year ago, despite already having strong liquidity to begin with. This would indicate improved cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 77.95% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY16||Q3 FY15|
|Net Sales ($mil)||4.67||1.34|
|Net Income ($mil)||-7.29||-3.82|
|Balance Sheet||Q3 FY16||Q3 FY15|
|Cash & Equiv. ($mil)||51.32||34.25|
|Total Assets ($mil)||70.47||59.49|
|Total Debt ($mil)||72.43||67.77|
|Profitability||Q3 FY16||Q3 FY15|
|Gross Profit Margin||19.38||-330.39|
|Return on Assets||65.49||-39.21|
|Return on Equity||0.0||0.0|
|Debt||Q3 FY16||Q3 FY15|
|Share Data||Q3 FY16||Q3 FY15|
|Shares outstanding (mil)||99.93||94.15|
|Div / share||0.0||0.0|
|Book value / share||-0.15||-0.73|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||2066198.0||114984.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.
|PLX NM||Peers 34.33||PLX NM||Peers 27.22|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
PLX's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
PLX's P/CF is negative making the measure meaningless.
|PLX NM||Peers 24.82||PLX NA||Peers 0.41|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
PLX's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|PLX NM||Peers 11.43||PLX -25.00||Peers 3.61|
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
PLX's P/B is negative making this valuation measure meaningless.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, PLX is expected to significantly trail its peers on the basis of its earnings growth rate.
|PLX 5.75||Peers 136.62||PLX 23.83||Peers 532.92|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
PLX is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
PLX significantly trails its peers on the basis of sales growth